Risk factors and outcome associated with the acquisition of linezolid-resistant Enterococcus faecalis
| Autor: | Esteban Gonzalez-Diaz, Samantha Flores-Treviño, Natalia Hernández-Morfin, Rayo Morfin-Otero, Héctor R. Pérez-Gómez, S. Esparza-Ahumada, Eduardo Rodríguez-Noriega, Elvira Garza-González, Gerardo León-Garnica, Paola Bocanegra-Ibarias, Christian Mendoza-Mujica |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty Linezolid-resistant medicine.drug_class 030106 microbiology Immunology Antibiotics Microbiology Enterococcus faecalis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Humans Immunology and Allergy 030212 general & internal medicine Antibiotic use Mexico Enterococcal infections Gram-Positive Bacterial Infections Retrospective Studies biology business.industry Mortality rate Linezolid Clindamycin Odds ratio biochemical phenomena metabolism and nutrition biology.organism_classification QR1-502 chemistry Risk factors Case-Control Studies bacteria business medicine.drug |
| Zdroj: | Journal of Global Antimicrobial Resistance, Vol 21, Iss, Pp 405-409 (2020) |
| ISSN: | 2213-7165 |
| Popis: | Objectives Linezolid is a synthetic oxazolidinone antibiotic frequently used to treat vancomycin-resistant enterococcal infections. Vancomycin-susceptible Enterococcus faecalis can develop resistance to linezolid in environments with excessive linezolid use. The aim of this study was to define risk factors and outcome associated with the acquisition of linezolid-resistant E. faecalis (LREfs). Methods A retrospective case–control study was designed including patients hospitalised from January 2014 to October 2017 at Hospital Civil de Guadalajara ‘Fray Antonio Alcalde’ in Guadalajara, Mexico. A total of 50 patients culture-positive for LREfs and 100 control patients hospitalised in the same room and time as the cases were included. Clinical and demographic data were collected and analysed. Results Risk factors for the presence of LREfs included prior linezolid use [odds ratio (OR) = 6.74], prior clindamycin use (OR = 6.72) and previous surgery (OR = 5.79). The mortality rate was 18% for LREfs cases versus 9% for controls. Conclusion LREfs has emerged and spread in our hospital, an environment in which linezolid use is considerable. Risk factors for LREfs are prior antibiotic use, including linezolid, and previous surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect